ESMO 24: SunRISes On J&J’s TAR-200 In Bladder Cancer

J&J acquired Taris in 2019 to gain access to TAR-200 and its drug delivery platform. Now, early clinical data suggest the product could delay or remove the need for cystectomy in several bladder cancer settings and the US healthcare giant is eyeing multi-blockbuster sales.

Johnson & Johnson's 2019 acquisition of privately held TARIS Biomedical LLC for an undisclosed sum is looking like a canny move after new data from early trials of its lead product, TAR-200, suggested it could change the way bladder cancer is treated.

Although not particularly innovative of itself – TAR-200 uses a silicone-based device to deliver gemcitabine continuously to the bladder –...